Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Prodromal Symptoms Predict the Onset of α-Synucleinopathies
    ABSTRACT & COMMENTARY

    Prodromal Symptoms Predict the Onset of α-Synucleinopathies

    July 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    CSF Biomarkers May Distinguish MSA from Lewy-Body Alpha-Synucleinopathies Before the Onset of Debilitating Symptoms

    Amyloid, Tau, Neurodegeneration Diagnostic Framework to Predict Memory Decline Before the Onset of Dementia

    Amyloid, Tau, Neurodegeneration Diagnostic Framework to Predict Memory Decline Before the Onset of Dementia

    Related Products

    Can Dietary Intervention Delay the Onset of Alzheimer’s Disease?

    Loss of Consciousness at Onset of Aneurysmal SAH: Poor Prognosis

    Keywords

    prodromal

    α-synucleinopathies

    By Harini Sarva, MD

    Assistant Professor of Clinical Neurology, Weill Cornell Medical College

    Dr. Sarva reports no financial relationships relevant to this field of study.

    SYNOPSIS: In this review of the common prodromal symptoms of α-synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, the authors provided a potential framework for a timeline of the development of these conditions, starting with these prodromal symptoms.

    SOURCE: Savica R, Bradley BF, Mielke MM. When do α-synucleinopathies start? An epidemiological timeline: A review. JAMA Neurol 2018;75:503-509.

    Alpha-synucleinopathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are chronic progressive neurodegenerative conditions that result from abnormal deposition of misfolded α-synuclein into neurons, and in the case of MSA, into oligodendrocytes. Although pathological hallmarks begin many years before their clinical diagnoses, several prodromal features have been described in various studies. Neuropathological and functional imaging studies suggest the development of a premotor stage of at least five years before the clinical diagnosis of PD. Common prodromal symptoms described in the literature include olfactory dysfunction, constipation and dysautonomia, anxiety and depression, and REM-sleep behavior disorder. Two epidemiological studies have shown that anosmia can be predictive of Lewy body pathology and DaTscan positivity. Constipation is among the most commonly reported symptoms and, on average, can predate the clinical features of PD by at least 10 years. Anxiety and depression are also very common and may predate PD motor symptoms by 20 years. REM-sleep behavior disorder, another
    very common premotor symptom, may assist in predicting conversion to clinical features of PD. New studies indicate a median conversion of 7.5 years to PD, DLB, or MSA. Because of the lack of concrete predictive value of any of these prodromal symptoms, Savica et al proposed a three-stage representation: Stage 1 begins with neuropathology and early manifestations such as anosmia; Stage 2 consists of anxiety and RBD; and Stage 3 involves the striatum and presentation of parkinsonian symptoms.

    COMMENTARY

    Although various prodromal symptoms have been identified and have expanded our knowledge about the pathology and clinical phenomena of α-synucleinopathies, there is still a gap in predicting the development of specific types of disorders based on these early manifestations. Further complicating the issue is that PD itself is not a single disorder and has multiple subtypes. Thus, while having several prodromal features simultaneously may increase predictability, exactly which subtype of PD will develop is difficult to determine. In addition, exactly how the α-synuclein pathology propagates is unclear despite Braak’s work and as shown by the clinical manifestations of DLB. The role of genetic and epigenetic factors in the development of these conditions is not understood entirely. Lastly, much of the work on prodromal features of these conditions has been performed on patients with PD and cannot be generalizable to atypical parkinsonisms, which are rare. The high misdiagnosis rate between PD and parkinsonisms further complicates the predictability of these prodromal symptoms. Thus, large-scale epidemiological studies of at least five years with radiological and biological specimens are needed to aid not only in the development of good biomarkers but also in assisting in better using these prodromal features to predict the diverse forms of these neurodegenerative disorders.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 37, No. 11) - July 2018
    July 1, 2018

    Table Of Contents

    Predicting the Risk of Late-onset Alzheimer’s Disease and Dementia Based on Common Genetic Variants

    Ufmylation and Brain Development: Effects of Gene Mutations

    Cannabidiol: Does It Help in Drug-resistant Epileptic Encephalopathies?

    Chemotherapy-induced Neuropathy in Childhood Cancer Survivors

    Prodromal Symptoms Predict the Onset of α-Synucleinopathies

    Dual Antiplatelet Therapy for Minor Ischemic Stroke or TIA

    Tenecteplase vs. Alteplase for Ischemic Stroke

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Executive Editor Leslie Coplin; Editor Jonathan Springston; and Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing